ImmunoGen, Inc. Announces Sanofi-Aventis (France) Licenses Expanded Access to the Company’s TAP Technology

August 13, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that sanofi-aventis has exercised its option under a 2006 agreement for expanded access to ImmunoGen’s Tumor-Activated Prodrug (TAP) technology.

Twitter
LinkedIn
Facebook
Email
Print

Alliances

Sanofi (France)